<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434640</url>
  </required_header>
  <id_info>
    <org_study_id>16742</org_study_id>
    <secondary_id>2014-005298-36</secondary_id>
    <nct_id>NCT02434640</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women</brief_title>
  <official_title>Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to investigate the safety and tolerability of BAY1128688 and
      to determine the concentration of this substance in blood after repeated administration by
      the oral route. The investigational substance will be administered in tablet form to healthy
      women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Treatment Emergent Adverse Events (TEAEs) with severity grading</measure>
    <time_frame>Up to 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md (maximum concentration) of BAY1128688 after multiple dose</measure>
    <time_frame>0, 15, 30, 60, 90min, 2, 3, 4, 6, 8, 12, 24h (24h: QD only)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav,md (average steady state concentration) of BAY1128688 after multiple dose</measure>
    <time_frame>0, 15, 30, 60, 90min, 2, 3, 4, 6, 8, 12, 24h (24h: QD only)</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>BAY1128688 [Dose1]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1128688 dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1128688 [Dose2]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1128688 dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1128688 [Dose3]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1128688 dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1128688 [Dose4]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1128688 dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match arm 1,2, 3 and 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1128688</intervention_name>
    <description>Part A: Single dose and multiple dose for 14 days (postmenopausal women)</description>
    <arm_group_label>BAY1128688 [Dose1]</arm_group_label>
    <arm_group_label>BAY1128688 [Dose2]</arm_group_label>
    <arm_group_label>BAY1128688 [Dose3]</arm_group_label>
    <arm_group_label>BAY1128688 [Dose4]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part A: Single dose and multiple dose for 14 days (postmenopausal women)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1128688</intervention_name>
    <description>Part B: Multiple dose for 28 days (premenopausal women)</description>
    <arm_group_label>BAY1128688 [Dose2]</arm_group_label>
    <arm_group_label>BAY1128688 [Dose3]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        PART A

          -  Postmenopausal state, revealed by

               1. Medical history. One of the following:

                    -  Natural menopause at least 12 months prior to first study drug
                       administration,

                    -  Surgical menopause by bilateral ovariectomy at least 3 months prior to first
                       study drug administration) or

                    -  Hysterectomy AND

               2. Follicle-stimulating hormone (FSH) &gt; 40 IU/L

          -  Age 45 to 68 years

        PART B

          -  Healthy female subjects

               -  Sterilized by tubal-ligation

               -  Pre-treatment menstrual cycle assessed as ovulatory

          -  Completion of more than 3 menstrual cycles after delivery, abortion or lactation

          -  Age 18 to 48 years

        Exclusion Criteria:

          -  Body mass index (kg/m2) greater or equal 32 (or less or equal 18)

          -  Smoking: PART A: non-smoking; PART B: less than 10 cigarettes per day

          -  Use of medicines including but not restricted to contraceptives and NSAIDs (details
             regarding previous use of medicines provided by the study center)

          -  Ability and willingness to adhere to restrictions regarding diet (PART A and B) and to
             eat standardised meals (PART A only)

          -  Significant diseases of the heart, gastrointestinal tract and/or liver and/or kidney
             and/or reproductive organs (present or in the past; details will be provided by the
             study center)

          -  Recent infectious diseases (details will be provided by the study center)

          -  Migraine or depression

          -  Thyroid disease which requires treatment

          -  Metabolic disorders, for example diabetes mellitus or hypertriglyceridemia

          -  Drug or alcohol abuse; regular consumption of more than 800 ml of beer per day (or
             other drinks resembling 40 g of alcohol)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neu-Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

